KATIE THAYER: Open Payments
NPI 1215562566 · WARWICK, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,419 in 206 payments from 16 companies in 2025. Trend: 2023 $4,052 · 2024 $3,717 · 2025 $4,419
Food & beverage: $4,419
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 26 | $644 |
| ABBVIE INC. | 25 | $625 |
| Otsuka America Pharmaceutical, Inc. | 27 | $531 |
| Alkermes, Inc. | 16 | $415 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $402 |
| Axsome Therapeutics, Inc. | 16 | $392 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $312 |
| Collegium Pharmaceutical, Inc. | 15 | $230 |
| Neurocrine BioSciences, Inc. | 8 | $220 |
| Tris Pharma Inc | 10 | $173 |
Products named: REXULTI, FANAPT, VRAYLAR, CAPLYTA, Auvelity, TRINTELLIX, ARISTADA, Jornay PM.
Industry payments across RI — which companies pay providers there.
